NCT03811132

Brief Summary

The DIA-LINK Study is a prospective observational study analysing longitudinal associations and mediating links between diabetes distress (DD), depressive symptoms (DS) and glycaemic outcomes in people with type 1 diabetes (T1DM). A total of 200 people with T1DM with different levels of DD and DS are to be enrolled. At baseline, all participants are assessed for DD and DS, psychological and stress-related variables, self-reported self-management, HbA1c and inflammatory markers. This is followed by a 4-week ambulatory assessment period including continuous glucose monitoring (CGM), continuous activity tracking and daily event sampling regarding sleep, stress levels, mood and diabetes-related issues; additionally, cortisol levels are assessed on four days within this period. Three months after baseline, a follow-up assessment covers DD and DS levels, stress-related variables, self-reported self-management, HbA1c and final CGM assessment. The analyses aim to establish risk factors/protective factors regarding DD and DS, their relative impact on glycaemic outcomes and potential mediation of the associations by behavioural (e.g. self-management, physical activity), physical (e.g. heart rate variability, inflammatory activity) and mental variables (subjective stress level) in T1DM.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
208

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2018

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2018

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

January 4, 2019

Completed
18 days until next milestone

First Posted

Study publicly available on registry

January 22, 2019

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2020

Completed
Last Updated

September 27, 2024

Status Verified

September 1, 2024

Enrollment Period

2 years

First QC Date

January 4, 2019

Last Update Submit

September 25, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Depressive symptoms

    Depressive symptoms are assessed using the 20-item Center for Epidemiologic Studies Depression Scale (CES-D), covering 20 symptoms of depression. Frequencies of the symptoms during the past week are scored on a 4-point Likert scale (from 0 - "rarely or non of the time" to 3 - "most or all of the time"). Item scores are summed to a total score ranging from 0 to 60, whereby higher values reflect higher depressive symptoms. A cut-off point at ≥ 22 points (found to have the best likelihood ratio for detecting depression within the German population) is used to establish elevated depressive symptoms in this study.

    3-month follow-up

  • Diabetes Distress

    Diabetes Distress is assessed as using the 20-item Problem Areas In Diabetes Scale (PAID). 20 potential problems related to living with diabetes are rated on a 5-point Likert scale (from 0 - "not a problem" to 4 - "serious problem"). Item scores are summed/transformed to a total score ranging from 0 to 100, whereby higher values reflect higher diabetes distress. A cut-off point at ≥ 40 points is commonly used to establish high diabetes distress, so too in this study.

    3-month follow-up

  • HbA1c

    HbA1c (estimated in %-points; mmol/mol values are calculated thereof) is used as a measure of glycaemic levels during past 3 months. It is estimated from a venous blood sample using high performance liquid chromatography (Tosho G11 analyser; meeting International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) standard) in this study. Higher values indicate less optimal glycaemic control, and values above 7.5% (58 mmol/mol) are considered to indicate glycaemic levels in need of improvement.

    3-month follow-up

Secondary Outcomes (17)

  • "Time in range" of glucose levels

    Continuous assessment over 4 weeks from baseline

  • Variability of glucose levels

    Continuous assessment over 4 weeks from baseline

  • "Time in hypoglycaemia" of glucose levels

    Continuous assessment over 4 weeks from baseline

  • "Time in hyperglycaemia" of glucose levels

    Continuous assessment over 4 weeks from baseline

  • Activity time

    Continuous assessment over 4 weeks from baseline

  • +12 more secondary outcomes

Other Outcomes (8)

  • Coping with stress

    Baseline

  • Resilience

    Baseline

  • Life events

    Baseline

  • +5 more other outcomes

Study Arms (4)

No DD or DS

No diabetes distress or depressive symptoms reported (CES-D \< 22, PAID \< 40)

Other: Observation

DD without DS

Diabetes distress but no depressive symptoms reported (CES-D \< 22, PAID ≥ 40)

Other: Observation

DS without DD

Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID \< 40)

Other: Observation

DD and DS

Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)

Other: Observation

Interventions

There is no intervention or group-specific procedure per observation groups. Each of the 4 groups is monitored using ecological momentary assessment (EMA) for diabetes-specific problems, mood, stress, diabete distress via a smartphone app over 26 days. Study is observational/non-interventional; specific groups are enrolled to enable specific comparisons between people with/without depressive symptoms and/or diabetes distress; no specific interventions are offered to neither group.

DD and DSDD without DSDS without DDNo DD or DS

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

People with T1DM with different levels of diabetes distress (DD) and/or depressive symptoms (DS): Four groups of n = 50 persons each reporting 1. "no DD/no DS" vs. 2. "DD/no DS" vs. 3. "DS/no DD" vs. "DD and DS".

You may qualify if:

  • Type 1 Diabetes
  • Diabetes duration at least 1 year
  • Age between 18 and 70 years
  • Sufficient German language skills
  • Informed consent
  • Smartphone available

You may not qualify if:

  • Capacity for consent lacking
  • Illness with significant impairment of cognitive functioning (e.g. dementia)
  • Severe somatic illness or mental disorder which interferes with study participation or might confound the results (dialysis-dependent renal failure; heart failure, i.e. New York Heart Association (NYHA) class III or IV; cancer requiring treatment; schizophrenia/psychotic disorder; bipolar disorder; severe eating disorder F50.0/F50.2; personality disorder)
  • Terminal illness
  • Being bedridden

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Diabetes Center Mergentheim

Bad Mergentheim, Baden-Wurttemberg, 97980, Germany

Location

Research Institute of the Diabetes Academy Mergentheim, Diabetes Center Mergentheim

Bad Mergentheim, Baden-Wurttemberg, 97980, Germany

Location

Related Publications (2)

  • Ehrmann D, Schmitt A, Priesterroth L, Kulzer B, Haak T, Hermanns N. Time With Diabetes Distress and Glycemia-Specific Distress: New Patient-Reported Outcome Measures for the Psychosocial Burden of Diabetes Using Ecological Momentary Assessment in an Observational Study. Diabetes Care. 2022 Jul 7;45(7):1522-1531. doi: 10.2337/dc21-2339.

    PMID: 35613338BACKGROUND
  • Schmitt A, Ehrmann D, Kuniss N, Muller N, Kulzer B, Hermanns N. Assessing fear of complications in people with type 1 and type 2 diabetes with the Fear of Diabetes Complications Questionnaire. Health Psychol. 2023 Sep;42(9):674-685. doi: 10.1037/hea0001304. Epub 2023 Jul 27.

Biospecimen

Retention: SAMPLES WITHOUT DNA

HbA1c; Cortisol; Markers of inflammation (hsCRP, IL-6, IL-1Ra, IL-18)

MeSH Terms

Conditions

Diabetes Mellitus, Type 1DepressionStress, Psychological

Interventions

Observation

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesBehavioral SymptomsBehavior

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Study Officials

  • Bernhard Kulzer, PhD

    Research Institute of the Diabetes Acadmey Mergentheim

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Prof. Dr. phil.

Study Record Dates

First Submitted

January 4, 2019

First Posted

January 22, 2019

Study Start

July 1, 2018

Primary Completion

June 30, 2020

Study Completion

June 30, 2020

Last Updated

September 27, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share

Locations